Known targets — ChEMBL curated mechanism
ABL1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB2AGTR1BCL2BCL2A1BCL2L1BCL2L10BCL2L2BCRBRAFCHRM1CHRNA10CHRNA9DRD1DRD2DRD3DRD4DRD5EGFRF2FLT1FLT4GCKGHSRGNRHRGRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BHTR1AHTR1BHTR1DHTR2AHTR2CHTR3AIDH2KDRKITMAOBMCL1MTTPPP4HBPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PIKFYVEROCK1ROCK2SLC18A2SLC6A2SLC6A3SLC6A4TACR1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8gyrAgyrBparCparEpol
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 known ✓ | P11229 | 4/20 | 0.38 |
| ▸ | DRD2 known ✓ | P14416 | 1/20 | 0.38 |
| ▸ | ADRA1D known ✓ | P25100 | 1/20 | 0.38 |
| ▸ | HTR2C known ✓ | P28335 | 1/20 | 0.38 |
| ▸ | ADRA1A known ✓ | P35348 | 1/20 | 0.38 |
| ▸ | ADRA1B known ✓ | P35368 | 1/20 | 0.38 |
| ▸ | KDR known ✓ | P35968 | 2/20 | 0.36 |
| ▸ | KIT known ✓ | P10721 | 1/20 | 0.36 |
| ▸ | FLT1 known ✓ | P17948 | 1/20 | 0.36 |
| ▸ | VEGFA | P15692 | 1/20 | 0.40 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.40 |
| ▸ | RECQL | P46063 | 2/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.38 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.38 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.38 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.38 |
| ▸ | PARP1 | P09874 | 5/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3063874 | 0.99 | VEGFA (0.41) | VEGFAEGLN1RECQLL3MBTL1ALDH1A1 | |
| SCHEMBL2778554 | 0.94 | L3MBTL1 (0.44) | RECQLL3MBTL1ALDH1A1TSHRCHRM1 | |
| SCHEMBL3054582 | 0.93 | L3MBTL1 (0.46) | VEGFAEGLN1RECQLL3MBTL1ALDH1A1 | |
| Hydrochloric Acid SCHEMBL3054664 | 0.92 | L3MBTL1 (0.45) | VEGFAEGLN1RECQLL3MBTL1ALDH1A1 | |
| SCHEMBL3060576 | 0.91 | KDR (0.39) | ALDH1A1PARP1KDRKITFLT1 | |
| SCHEMBL3062082 | 0.90 | PARP1 (0.42) | L3MBTL1ALDH1A1DRD2PARP1ACHE | |
| SCHEMBL3060549 | 0.90 | KDR (0.37) | PARP1KDRKITFLT1 | |
| SCHEMBL3054604 | 0.87 | DHODH (0.37) | L3MBTL1PARP1KDRKITFLT1 | |
| SCHEMBL3049186 | 0.87 | DHODH (0.37) | L3MBTL1PARP1KDRKITFLT1 | |
| SCHEMBL3049179 | 0.87 | DHODH (0.37) | L3MBTL1PARP1KDRKITFLT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100261706-A1 | SUBSTITUTED TETRACYCLIC 1H-INDENO [1,2-B]PYRIDINE-2(5H)-ONE ANALOGS THEREOF AND USES THEREOF | INOTEK PHARMACEUTICALS CORPORATION (US) | 2010-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100261706-A1 | SUBSTITUTED TETRACYCLIC 1H-INDENO [1,2-B]PYRIDINE-2(5H)-ONE ANALOGS THEREOF AND USES THEREOF | TNNI3, TNNT2, ALDH1A2 | CHRM1 814/4885DRD2 2481/4885ADRA1D 61/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.